Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.45 |
| ▸ | FDPS | P14324 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7079424 | 0.88 | SMN1; SMN2 (0.50) | SMN1; SMN2HIF1ASLC6A2TAAR1PLA2G10 | |
| SCHEMBL20913002 | 0.88 | SMN1; SMN2 (0.50) | SMN1; SMN2HIF1ASLC6A2TAAR1PLA2G10 | |
| SCHEMBL28824751 | 0.86 | SMN1; SMN2 (0.48) | SMN1; SMN2HIF1ASLC6A2TAAR1PLA2G10 | |
| SCHEMBL28276485 | 0.84 | SMN1; SMN2 (0.43) | SMN1; SMN2HIF1ASLC6A2TAAR1PLA2G10 | |
| SCHEMBL16892950 | 0.83 | GGPS1 (0.54) | SMN1; SMN2HIF1A | |
| SCHEMBL3077561 | 0.82 | HIF1A (0.57) | SMN1; SMN2HIF1ASLC6A2TAAR1PLA2G10 | |
| SCHEMBL338742 | 0.81 | SMN1; SMN2 (0.61) | SMN1; SMN2HIF1ASLC6A2TAAR1FDPS | |
| SCHEMBL10483829 | 0.80 | HIF1A (0.55) | SMN1; SMN2HIF1ASLC6A2TAAR1PLA2G10 | |
| SCHEMBL28125890 | 0.80 | HIF1A (0.55) | SMN1; SMN2HIF1ASLC6A2TAAR1PLA2G10 | |
| SCHEMBL8759 | 0.80 | SLC6A2 (0.56) | SMN1; SMN2HIF1ASLC6A2TAAR1PLA2G10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3662089-A1 | METHOD FOR SEPARATING PALLADIUM FROM OTHER METAL ELEMENTS PRESENT IN AN AQUEOUS NITRIC PHASE USING SPECIFIC MALONAMIDES AS EXTRACTANTS | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2020-06-10 | — | — | EP | claimed |
| CN-118290285-A | Method for synthesizing amide | 中国石油化工股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-3662089-A1 | METHOD FOR SEPARATING PALLADIUM FROM OTHER METAL ELEMENTS PRESENT IN AN AQUEOUS NITRIC PHASE USING SPECIFIC MALONAMIDES AS EXTRACTANTS | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2020-06-10 | — | — | EP | disclosed |
| EP-1896395-B1 | MODIFIED MALONATE DERIVATIVES | MERCK SHARP & DOHME (US) | 2015-07-15 | — | — | EP | disclosed |
| US-8158825-B2 | Modified malonate derivatives | MERCK SHARP & DOHME CORP. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100160327-A1 | Modified Malonate Derivatives | MERCK SHARP & DOHME LLC | 2010-06-24 | — | — | US | disclosed |
| US-20040073038-A1 | Process of preparing paroxetine and intermediates for use therein | SPURCOURT LIMITED (GB) | 2004-04-15 | — | — | US | disclosed |
| EP-1362032-A2 | PROCESS OF PREPARING PAROXETINE AND INTERMEDIATES FOR USE THEREIN | Spurcourt Limited (GB) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002068416-A2 | PROCESS OF PREPARING PAROXETINE AND INTERMEDIATES FOR USE THEREIN | SPURCOURT LIMITED (GB) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160327-A1 | Modified Malonate Derivatives | ME2, ME3, ME1 | SMN1; SMN2 651/4885HIF1A 1546/4885SLC6A2 3584/4885 |
| US-20040073038-A1 | Process of preparing paroxetine and intermediates for use therein | CYP2D6, CYP2C19, CYP2B6 | SMN1; SMN2 3809/4885HIF1A 2269/4885SLC6A2 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.